Published: May 01, 2021
Expanded indications for patients with sickle cell disease or other anemias, as well as thalassemia
BOSTON, May 1, 2021 /PRNewswire/ Chiesi Global Rare Diseases, a business unit of
Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the U.S. Food & Drug Administration (FDA) has approved FERRIPROX
® (deferiprone) for the treatment of transfusional iron overload due to sickle cell disease (SCD) or other anemias in adult and pediatric patients 3 years of age and older. This FDA approval expands the use of FERRIPROX for patients with SCD or other anemias as well as patients with thalassemia regardless of prior iron chelation exposure.
/PRNewswire/ Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group),.